
Healthesystems is attending the IAIABC Forum, a conference discussing policy and administrative issues in workers' comp.

Healthesystems is attending the IRSG Conference, which is designed for leaders in the insurance, medical, and rehabilitation fields.
Approval Date: Mar 2026
An inhaled corticosteroid indicated for the maintenance treatment of asthma as a prophylactic therapy, and for the treatment of asthma in patients requiring oral corticosteroids
Approval Date: Feb 2026
Indicated for the treatment of partial-onset seizures
Approval Date: Feb 2026
Indicated for the treatment of partial-onset seizures
Approval Date: Jan 2026
An opioid analgesic indicated for the relief of moderate to severe pain
Approval Date: Jan 2026
An opioid analgesic indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in patients weighing at least 40 kg
Approval Date: Jan 2026
Indicated as a complete regimen for the treatment of HIV-1 infection in patients weighing at least 35 kg as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies per mL; or to replace a stable antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) for at least six months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Odefsey
Approval Date: Jan 2026
Indicated for the treatment of rheumatoid arthritis, giant cell arthritis, cytokine release syndrome, and COVID-19
Approval Date: Dec 2025
Indicated for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype (a type of inflammation characterized by high levels of white blood cells) in patients
Approval Date: Dec 2025
Indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in obese adults and overweight adults with at least one weight-related comorbidity. This approval is for a new oral tablet formulation of Wegovy, making it the first orally available GLP-1 medication for obesity.
Approval Date: Dec 2025
Indicated for the treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
Approval Date: Dec 2025
A biosimilar to Prolia® (denosumab), this drug is a RANKL inhibitor indicated for the treatment of osteoporosis in postmenopausal women with high risk of fracture, to increase bone mass in men with osteoporosis at a high risk for fracture, for the treatment of glucocorticoid-induced osteoporosis in men and women with high risk of fracture, and more
Approval Date: Dec 2025
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, this approval is for a first-time generic
Approval Date: Nov 2025
Indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern. This approval is for a first-time generic
Approval Date: Oct 2025
Indicated for the treatment of hypertension to lower blood pressure, a new oral solution formulation of this drug is now available
Approval Date: Sep 2025
A lidocaine and amide local anesthetic patch indicated for the relief of pain associated with post-herpetic neuralgia (shingles pain)